Hormone replacement therapy and heart-rate variability [9]

Lancet

Volumn 354, Issue 9174, 1999, Pages 256-

  Hayward, C S ^a   Webb, C M ^a   Collins, P ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; FEMALE; HEART RATE VARIABILITY; HORMONE SUBSTITUTION; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 0033578254     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66330-1     Document Type: Letter

References (4)

1. M Christ K Seyffart M Wehling Attenuation of heart-rate variability in postmenopausal women on progestin-containing hormone replacement therapy Lancet 353 1999 1939 1940
2. S Hulley D Grady T Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
3. K Miyagawa J Rosch F Stanczyk K Hermsmeyer Medroxyprogesterone interferes with ovarian steroid protection against coronary spasm Nat Med 3 1997 324 327
4. GMC Rosano PM Sarrel SL Chierchia Medroxyprogesterone, but not natural progesterone, reverses the beneficial effect of estradiol 17beta upon exercise-induced myocardial ischemia Circulation 94 1996 1 18